Figures & data
Figure 1. Tumor antigens are cross-presented by DCs residing in tumor-draining lymph nodes (DLNs) leading to expansion of endogenous tumor-specific CTLs. However, the inability of tumor-infiltrating DCs (TiDCs) to cross-present tumor antigen may lead to a lack of efficient proliferation and activation of infiltrating antigen-specific CD8+ T cells at the effector site. This failure of post-licensing within the tumor microenvironment may limit the generation of an effective antitumor immune response, explaining the failure of endogenous, vaccine-derived, or adoptively transferred CD8+ T cells to kill tumors.
